Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL2L1 | Q07817 | 20/20 | 1.00 |
| ▸ | BCL2 | P10415 | 16/20 | 1.00 |
| ▸ | ALB | P02768 | 1/20 | 1.00 |
| ▸ | BCL2L2 | Q92843 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL681275 | 1.00 | BCL2L1 (1.00) | BCL2L1BCL2ALBBCL2L2 | |
| SCHEMBL31384063 | 1.00 | BCL2L1 (1.00) | BCL2L1BCL2ALBBCL2L2 | |
| SCHEMBL2946904 | 0.97 | BCL2L1 (0.95) | BCL2L1BCL2ALBBCL2L2 | |
| SCHEMBL2949972 | 0.95 | BCL2L1 (1.00) | BCL2L1BCL2ALBBCL2L2 | |
| SCHEMBL2950813 | 0.94 | BCL2L1 (0.89) | BCL2L1BCL2ALBBCL2L2 | |
| SCHEMBL376333 | 0.93 | BCL2L1 (0.86) | BCL2L1BCL2ALBBCL2L2 | |
| SCHEMBL2945317 | 0.91 | BCL2L1 (0.83) | BCL2L1BCL2ALBBCL2L2 | |
| SCHEMBL2951513 | 0.90 | BCL2L1 (1.00) | BCL2L1BCL2ALBBCL2L2 | |
| SCHEMBL4465505 | 0.90 | BCL2L1 (0.88) | BCL2L1BCL2ALBBCL2L2 | |
| SCHEMBL3953783 | 0.89 | BCL2L1 (0.82) | BCL2L1BCL2ALBBCL2L2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3331546-B1 | CXCR4 INHIBITOR FOR THE TREATMENT OF CANCER | BIOKINE THERAPEUTICS LTD (IL) | 2023-10-04 | — | — | EP | disclosed |
| US-20210251944-A1 | METHODS FOR TREATING A CANCER RESISTANT TO AT LEAST ONE TYROSINE KINASE INHIBITOR | DEL MAR PHARMACEUTICALS (BC) LTD. (CA) | 2021-08-19 | — | — | US | disclosed |
| US-11092602-B2 | Methods and compositions relating to proteasome inhibitor resistance | WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2021-08-17 | — | — | US | disclosed |
| EP-2872161-B1 | DIANHYDROGALACTITOL FOR USE IN TREATING TYROSINE-KINASE-INHIBITOR-RESISTANT MALIGNANCIES IN PATIENTS WITH GENETIC POLYMORPHISMS OR AHI1 DYSREGULATIONS OR MUTATIONS | DEL MAR PHARMACEUTICALS (CA) | 2020-12-16 | — | — | EP | disclosed |
| US-20180306796-A1 | METHODS AND COMPOSITIONS RELATING TO PROTEASOME INHIBITOR RESISTANCE | HOWARD HUGHES MEDICAL INSTITUTE | 2018-10-25 | — | — | US | disclosed |
| US-20180221393-A1 | CXCR4 BINDING AGENTS FOR TREATMENT OF DISEASES | KREOS CAPITAL V (EXPERT FUND) L.P. (JE) | 2018-08-09 | — | — | US | disclosed |
| EP-3331546-A1 | CXCR4 BINDING AGENTS FOR TREATMENT OF DISEASES | Biokine Therapeutics Ltd. (IL) | 2018-06-13 | — | — | EP | disclosed |
| WO-2017021963-A1 | CXCR4 BINDING AGENTS FOR TREATMENT OF DISEASES | BIOKINE THERAPEUTICS LTD. (IL) | 2017-02-09 | — | — | WO | disclosed |
| WO-2017007858-A1 | METHODS AND COMPOSITIONS RELATING TO PROTEASOME INHIBITOR RESISTANCE | WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2017-01-12 | — | — | WO | disclosed |
| US-20150182490-A1 | METHODS FOR TREATING TYROSINE-KINASE-INHIBITOR-RESISTANT MALIGNANCIES IN PATIENTS WITH GENETIC POLYMORPHISMS OR AHI1 DYSREGULATIONS OR MUTATIONS EMPLOYING DIANHYDROGALACTITOL, DIACETYLDIANHYDROGALACTITOL, DIBROMODULCITOL, OR ANALOGS OR DERIVATIVES THEREOF | DEL MAR PHARMACEUTICALS (BC) LTD. (CA) | 2015-07-02 | — | — | US | disclosed |
| EP-2872161-A2 | METHODS FOR TREATING TYROSINE-KINASE-INHIBITOR-RESISTANT MALIGNANCIES IN PATIENTS WITH GENETIC POLYMORPHISMS OR AHI1 DYSREGULATIONS OR MUTATIONS EMPLOYING DIANHYDROGALACTITOL, DIACETYLDIANHYDROGALACTITOL, DIBROMODULCITOL, OR ANALOGS OR DERIVATIVES THEREOF | Del Mar Pharmaceuticals (CA) | 2015-05-20 | — | — | EP | disclosed |
| US-20150056186-A1 | COMBINATION THERAPY OF A TYPE II ANTI-CD20 ANTIBODY WITH AN ANTI-BCL-2 ACTIVE AGENT | HOFFMANN-LA ROCHE INC. (US) | 2015-02-26 | — | — | US | disclosed |
| WO-2014004376-A2 | METHODS FOR TREATING TYROSINE-KINASE-INHIBITOR-RESISTANT MALIGNANCIES IN PATIENTS WITH GENETIC POLYMORPHISMS OR AHI1 DYSREGULATIONS OR MUTATIONS EMPLOYING DIANHYDROGALACTITOL, DIACETYLDIANHYDROGALACTITOL, DIBROMODULCITOL, OR ANALOGS OR DERIVATIVES THEREOF | DEL MAR PHARMACEUTICALS (CA) | 2014-01-03 | — | — | WO | disclosed |
| US-20140004104-A1 | COMBINATION THERAPY OF A TYPE II ANTI-CD20 ANTIBODY WITH AN ANTI-BCL-2 ACTIVE AGENT | HOFFMANN-LA ROCHE INC. (US) | 2014-01-02 | — | — | US | disclosed |
| EP-2604277-A1 | Combination therapy of a type II anti-CD20 antibody with an anti-Bcl-2 active agent | Roche Glycart AG (CH) | 2013-06-19 | — | — | EP | disclosed |
| US-20120276085-A1 | COMBINATION THERAPY OF A TYPE II ANTI-CD20 ANTIBODY WITH AN ANTI-BCL-2 ACTIVE AGENT | Hoffman-La Roche. Inc. (US) | 2012-11-01 | — | — | US | disclosed |
| US-20110287006-A1 | COMBINATION THERAPY OF A TYPE II ANTI-CD20 ANTIBODY WITH AN ANTI-BCL-2 ACTIVE AGENT | Hoffman-La Roche. Inc. (US) | 2011-11-24 | — | — | US | disclosed |
| US-20110086025-A1 | Combination Therapy of a Type II Anti-CD20 Antibody with an Anti-BCL-2 Active Agent | Hoffman-La Roche. Inc. (US) | 2011-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150056186-A1 | COMBINATION THERAPY OF A TYPE II ANTI-CD20 ANTIBODY WITH AN ANTI-BCL-2 ACTIVE AGENT | BAK1, BCL2, BCL3 | BCL2L1 7/4885BCL2 2/4885ALB 4760/4885 |
| US-20150182490-A1 | METHODS FOR TREATING TYROSINE-KINASE-INHIBITOR-RESISTANT MALIGNANCIES IN PATIENTS WITH GENETIC POLYMORPHISMS OR AHI1 DYSREGULATIONS OR MUTATIONS EMPLOYING DIANHYDROGALACTITOL, DIACETYLDIANHYDROGALACTITOL, DIBROMODULCITOL, OR ANALOGS OR DERIVATIVES THEREOF | WHR1, AIPL1, TDP1 | BCL2L1 40/4885BCL2 300/4885ALB 4845/4885 |
| US-20210251944-A1 | METHODS FOR TREATING A CANCER RESISTANT TO AT LEAST ONE TYROSINE KINASE INHIBITOR | DCLRE1B, AIPL1, WHR1 | BCL2L1 43/4885BCL2 341/4885ALB 4848/4885 |
| US-11092602-B2 | Methods and compositions relating to proteasome inhibitor resistance | PSMG3, PSMB1, PSMB11 | BCL2L1 922/4885BCL2 553/4885ALB 3944/4885 |
| US-20110287006-A1 | COMBINATION THERAPY OF A TYPE II ANTI-CD20 ANTIBODY WITH AN ANTI-BCL-2 ACTIVE AGENT | BAK1, BCL2, BCL3 | BCL2L1 7/4885BCL2 2/4885ALB 4760/4885 |
| US-20120276085-A1 | COMBINATION THERAPY OF A TYPE II ANTI-CD20 ANTIBODY WITH AN ANTI-BCL-2 ACTIVE AGENT | BAK1, BCL2, BCL3 | BCL2L1 7/4885BCL2 2/4885ALB 4760/4885 |
| US-20110086025-A1 | Combination Therapy of a Type II Anti-CD20 Antibody with an Anti-BCL-2 Active Agent | BAK1, BCL2, BCL3 | BCL2L1 7/4885BCL2 2/4885ALB 4760/4885 |
| US-20180221393-A1 | CXCR4 BINDING AGENTS FOR TREATMENT OF DISEASES | CXCL12, CXCR4, CXCR1 | BCL2L1 21/4885BCL2 14/4885ALB 4694/4885 |
| US-20140004104-A1 | COMBINATION THERAPY OF A TYPE II ANTI-CD20 ANTIBODY WITH AN ANTI-BCL-2 ACTIVE AGENT | BAK1, BCL2, BCL3 | BCL2L1 7/4885BCL2 2/4885ALB 4760/4885 |
| US-20180306796-A1 | METHODS AND COMPOSITIONS RELATING TO PROTEASOME INHIBITOR RESISTANCE | PSMG3, PSMB1, PSMB11 | BCL2L1 922/4885BCL2 553/4885ALB 3944/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.